Drug Profile
Vocimagene amiretrorepvec-flucytosine gene therapy - Denovo Biopharma
Alternative Names: DB-107; Flucytosine prodrug activating therapy - Forte Biosciences; Retroviral replicating viral; RRV; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosineLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Tocagen
- Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Immunotherapies; Pyrimidinones; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Gene transference; Prodrug activators; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Anaplastic astrocytoma; Bladder cancer; Breast cancer; Glioblastoma; Glioma; Solid tumours
Most Recent Events
- 20 Feb 2024 Denovo Biopharma plans a phase II trial for Glioblastoma and Anaplastic astrocytoma (Recurrent, Inoperable/unresectable) in USA (PO), in May 2024 (NCT06264388)
- 25 Jul 2023 US FDA authorizes a phase II trial for DB 107 in Glioma
- 25 Jul 2023 Denovo Biopharma plans a phase II trial in Glioma (First-line therapy)